Venclyxto is a Cancer Drug Known to Adults as CLL

Venclyxto is a cancer drug known to adults as chronic lymphocytic leukemia (CLL).

Venclyxto can be used in combination with rituximab (another cancer drug) in patients who have received at least one previous treatment.

It can also be used by itself:

Especially patients with genetic alterations (17p deletions or TP53 mutations) that make them unsuitable for chemo-immunotherapy (a type of cancer treatment). In these patients, Venclyxto is used when drugs known as B cept cell receptor pathway inhibitors (ibrutinib and idelalisib) are not suitable or fail.
Patients who do not have these genetic changes after treatment with chemo-immunotherapy and B cept cell receptor pathway inhibitors have both failed.
The active substance in venclyxto is venetoclax.

Venclyxto is to be taken with food once a day in the form of tablets (10, 50 and 100 mg). The initial dose is 20 mg daily and the dose is gradually increased to 400 mg over 5 weeks.

When Venclyxto is used in combination with Raximab, the recommended dose of Venclyxto is 400 mg once a day. Patients should have taken Vanclexto at a daily dose of 400 mg for 7 days before beginning therapy with the ritual. The day of the first cycle of the Venclyxto ritual should be taken for 1 to 24 months.

When Venclyxto is used on its own, treatment should continue until the patient improves or remains stable and side effects are tolerable. If the patient experiences some side effects, the treatment may be temporarily stopped or the dose may be reduced.

Venclyxto should be initiated and supervised by a doctor with experience in cancer drugs and can only be obtained with a prescription.

For more information about using venclyxto, see the package sheet or contact your doctor or pharmacist.

Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more